WUND Healing Biopharmaceuticals, Inc. has filed an amended offering statement with the SEC to raise up to $10 million through a Regulation A Tier 2 offering. This significant move is aimed at bolstering the company's financial resources as it navigates the competitive landscape of the pharmaceutical industry.

The offering involves 1 million shares of common stock, priced at $10 each, and will be conducted on a 'best-efforts' basis. This means that there is no minimum number of shares that must be sold for the offering to close, allowing WUND to potentially receive minimal proceeds. Investors should be aware that all proceeds will become immediately available to the company and may be used as they are accepted.

Background

WUND Healing Biopharmaceuticals, Inc. is a Nevada-based company focused on the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. The company was incorporated in 2016 and has been actively seeking ways to enhance its capital structure through various offerings. Recent filings include amendments to its offering statement, with the latest filed on October 30, 2026, under the accession number 0001477932-26-006556.

What the Filing Says

The filing details that the company is offering up to 1 million shares, with a total aggregate offering of $10 million. It states, "This is a Regulation A Tier 2 offering of securities of WUND Healing Biopharmaceuticals, Inc." The company has engaged Benjamin Securities, Inc. as placement agents for this offering, which includes a fee of 6.5% of the aggregate offering price of the shares sold.

Impact

This offering may significantly affect WUND's operational capacity, allowing it to fund its projects and initiatives within the pharmaceutical preparations industry. Investors in the offering will be required to meet certain thresholds, and the company has cautioned that investment in its stock involves significant risk.

What's Next

The offering is expected to commence within two days of SEC qualification. However, it may terminate at the earliest of the date on which the maximum offering has been sold, one year from the date of SEC qualification, or at the discretion of the company. The filing does not specify what happens next beyond this timeline.